The Chemistry Department within the Southern Research Drug Discovery division houses a team of chemists with extensive experience in both medicinal chemistry and synthetic organic chemistry. Current research and drug discovery programs cover a large range of various disease areas including antivirals and emerging pathogens, Parkinson’s and Alzheimer’s disease, ALS, diabetes, cancer, and psychiatric disorders. One of the Chemistry Department’s main goals is to identify and bring forth compounds that can be classified as potential preclinical candidates and then collaborate with partners to advance these compounds into human clinical trials. Additionally, basic research is carried out as we explore compounds that may be used as tools to investigate novel targets. Several existing collaborative relationships exist between the department and external partners, such as universities, research centers, and the National Institute of Health (NIH). The department encompasses various disciplines in addition to synthetic chemistry, such as structural biology and protein crystallography, computational chemistry and high throughput synthesis and purification capabilities, as well and informatics tools to process and track data.
Chemistry Department Senior Staff
Chemistry Lab Personnel
Garzan received her doctorate in organic chemistry from Michigan State University and her Master of Science in organic chemistry from Shiraz University. After completing her doctorate, she joined Professor Wipf’s group at the University of Pittsburgh working on a new class of STAT3 pathway inhibitors. In 2013, she joined Professor Garneau-Tsodikova’s group at the University of Kentucky College of Pharmacy, where she worked on the identification, synthesis, and SAR studies of compounds possessing activity in the low nanomolar range against an enzyme responsible for extensive drug resistance (XDR) in Mycobacterium tuberculosis. Garzan joined Southern Research in 2017 as an associate research chemist. She is currently working in the area of antiviral drug discovery in the Antiviral Drug Discovery and Development Center (AD3C), one of the Centers of Excellence for Translation Research (CETR). She is responsible for providing synthetic chemistry efforts of various target compounds as potential therapeutics for the treatment of Chikungunya virus (CHIKV). Garzan is co-author of 16 peer-reviewed scientific publications. Publications
Mathew received a doctorate in organic chemistry from Mahatma Gandhi University by working at the National Institute for Interdisciplinary Science & Technology. She completed a post-doctoral fellowship at the University of Konstanz, Germany, as an Alexander von Humboldt Fellow, followed by a post-doctoral fellowship at Ohio State University. She gained more than 14 years of research experience in medicinal chemistry, heterocyclic chemistry, carbohydrate chemistry, total synthesis of natural products, and discovery and lead optimization of small molecules for the development of novel drugs. Currently, she focuses on structure-based drug discovery for cancer and infectious diseases. Mathew has authored several peer-reviewed publications, and she is an inventor on several patents. She received the Southern Research Excellence Award in 2010 and 2015. Currently, Mathew is working on various collaborative projects between SR and the University of Alabama at Birmingham, such as Heme Oxygenase -1 Activation for Kidney Disease, NF-kB activation for the treatment of ALS, and TSP-1 mediated TGF-Î² activation for potential treatment of multiple myeloma. Publications
John Tillotson, Ph.D, received his Doctorate in Physical Organic Chemistry and his Bachelor’s in Chemistry from the Georgia Institute of Technology. Under Professor Joseph W. Perry, Ph.D., his doctoral research focused on investigating the structure-property relationships of organic chromophores with hypersensitivity to electric fields for use in second harmonic generation (SHG) sensing and imaging of neuronal interactions. Through his efforts and in conjunction with Dr. Joel Hales, Tillotson developed a novel screening method for SHG sensitivity to electric fields based on neuronal membrane mimics. He joined Southern Research in 2019 and is currently working on novel countermeasures for skin exposure to chemical vesicants and TGF-β activation for the treatment of multiple myeloma under the direction of Dr. Bini Matthew.
Rodzinak received his Bachelor of Science in chemistry and biology from Misericordia University, Dallas, Pennsylvania. He joined Southern Research in May 2016 and is currently a research chemist in the Chemistry Department. Prior to joining Southern Research, Rodzinak was employed by noted companies such as Merck Research Laboratories and DuPont/Merck Research Laboratories. At these organizations, he contributed to the identification and lead optimization space in a variety of therapeutic areas and drug target classes. With over 18 years of experience in drug discovery from various projects at these pharmaceutical companies, he continues to design and synthesize molecules in various therapeutic areas with a current focus on antivirals and anti-HIV therapeutics. Rodzinak was a key contributor in the NMDA, PDE9, PDE10, and mGluR2 therapeutic areas. He was instrumental in the discovery and design of MK-2206 for the treatment of cancer, which is currently in Phase II of clinical trials. He is also an inventor on 13 patents and has published three peer-reviewed manuscripts describing his work of novel chemical compounds. Publications
Larry Bratton earned his Master’s of Science in Organic Chemistry from Texas Tech University under Professor Richard Bartsch where he prepared several crown compounds for extraction of heavy metals from waste water. He has more than 24 years of research experience in process, organic, and medicinal chemistry designing and synthesizing polymers, natural products, prostaglandins, and various heterocycles as new candidates for drugs, tools for biological research, and forensic science. Prior to joining Southern Research, Bratton worked for several pharmaceutical companies conducting research in therapeutic areas of cardiovascular, inflammation, CNS, allergy, and, dermatology. Bratton is a primary author on six peer-reviewed scientific publications, a co-author on nine scientific publications, and a co-inventor on 15 issued US Patents.
Dr. Fosso Yatchang received her Doctorate in 2007 in Organic Chemistry from Utah State University under the supervision of Prof. Cheng-Wei Tom Chang. As part of her graduate work, she utilized carbohydrates to synthesize antibacterial and antifungal agents, along with potential therapeutics for spinal muscular atrophy. In 2013, following her Doctorate, Marina joined the group of Prof. Sylvie Garneau-Tsodikova in the College of Pharmacy at the University of Kentucky. As a Postdoctoral Scholar in Organic/Medicinal Chemistry, she developed novel multi-functional molecules for the treatment of Alzheimer’s disease. She also applied her expertise in aminoglycoside for the development of therapies against infectious diseases. She joined the Chemistry Department in 2018 as Scientist, where she is involved in the development of effective countermeasures to the deleterious effects that result from the exposure to arsenicals, providing medicinal chemistry efforts to the synthesis of inhibitors of identified critical pathways.
Venukadasula earned his doctorate from the University of Kansas and his master’s from the University of Hyderabad, where his work involved the development of several phosphate-tether mediated one-pot metathesis processes and their application in synthesis of bio-active small molecules. SR accomplishments include: synthesis of a variety of target compounds; structure-activity relationships; and scientific findings shared via peer-reviewed publications and patent applications. One of his major contributions is the identification of inhibitors of three proteases – matriptase, hepsin and HGFA, as potential anticancer agents. This work resulted in the only known small molecule inhibitor of HGFA. These inhibitors were also selective against off-target enzymes, such as thrombin and factor Xa. He worked on small molecule inducers of 14-3-3Ө expression as a potential therapy for Parkinson’s disease. He designed and synthesized a series of compounds of which one analog has been identified as a potent lead compound. His current research involves the design, synthesis and development of small molecule inhibitors of HIV-Vif dimerization and inhibitors of Vif-mediated degradation of A3G as novel targets for development of HIV-targeted drugs. Publications
Deimler obtained his doctorate in analytical chemistry from West Virginia University and his Bachelor of Science in chemistry from Georgia College and State University. His graduate studies focused on the development of a new fragmentation technique for mass spectrometry, metastable atom-activated dissociation (MAD), a project which sought to investigate the viability of laser ablation electrospray ionization (LAESI) for forensic drug testing. While participating in these projects, Deimler developed an interest in repairing, improving, and utilizing analytical instruments. At Southern Research, his current expertise focuses on liquid chromatography and mass spectrometry. Publications
Tanner received his master’s in synthetic organic chemistry from the University of Alabama at Birmingham. The focus of his graduate work was the synthesis of novel blockers of the voltage-gated sodium channels as a potential therapeutics to treat breast and prostate cancers. Tanner joined the Southern Research in May 2016, focusing his efforts on the synthesis of small molecule inhibitors as potential therapeutics for the treatment of influenza and HIV-1 research. Publications
Karyakarte received his doctorate in organic chemistry from the State University of New York at Buffalo. Under Professor Sherry Chemler, his doctoral research focused on developing efficient routes towards the stereoselective syntheses of structurally diverse saturated oxygen and nitrogen heterocycles using copper (II)-mediated difunctionalizations of unactivated alkenes. Subsequently, Karyakarte joined Boehringer Ingelheim Pharma Inc. in Ridgefield, Connecticut, as a post-doctoral intern, where, under the supervision of Dr. Chris Senanayake and his team, he worked on the rational design and synthesis of novel ligands and their applications in diverse and useful organic transformations. He joined SR in 2017 as a postdoctoral fellow and is currently working in the area of antiviral drug discovery in the Antiviral Drug Discovery and Development Center (AD3C), one of the Centers of Excellence for Translation Research (CETR), funded through NIAID, NIH. He is provides synthetic chemistry efforts of various target compounds as potential therapeutics for the treatment of Chikungunya virus (CHIKV) and Venezuelan equine encephalitis virus (VEEV). Publications: NCBI, Google Scholar
Dr. Zhang has 10+ years of experience in computational chemistry. He obtained his B.S. of chemistry at Fudan University (Shanghai, China) with the Samsung Scholarship. He also received research experience in biochemistry from the Institute of Biomedical Science with the Tsung-dao Lee Scholarship and computer-aided drug discovery from the Pharmacy School with the Qihang Scholarship. He then obtained his Ph.D. of computational chemistry at University of Illinois Urbana-Champaign with the J. & M. Witt Fellowship under the supervision of Professor Sharon Hammes-Schiffer. Since joining Southern Research in 2016, he has participated in research and decision making in more than 40 computer-aided drug discovery projects in a multidiscipline platform with collaborations from more than 15 different institutions, covering oncology, neuroscience, infectious diseases, and genetic disorders. He successfully designed compounds that showed proof-of-concept in animal studies or co-crystalized with target proteins, which yielded high-impact publications as well as multiple awards. His expertise includes computational chemistry, computational biology, cheminformatics, bioinformatics, and machine learning. He also serves as a review editor of scientific journals and speaker at national and international conferences.
Ahmed joined SR in 2014 as an associate research chemist, and has now advanced to research chemist. He received his doctorate in medicinal chemistry from the Indian Institute of Chemical Technology, Hyderabad, India. Subsequently, he conducted post-doctoral studies at the University of Alabama at Birmingham (UAB) and at the University of Montana (UM) in the areas of medicinal chemistry, organophosphate agents, and radiotracer development. Prior to joining SR, he was a senior research scientist within the Department of Biomedical and Pharmaceutical Sciences at UM. His interest in PET imaging chemistry is focused on the development of radio-labelled CNS and anti-cancer drug candidate. He is also interested in the area of infectious diseases with a focus on development of anti-viral agents targeting flaviviruses, coronaviruses, and alphaviruses. He is a member of the American Chemical Society and the International Union of Pure and Applied Chemistry. He is a reviewer for Science Direct, Bentham Science, and peer-reviewed journals, and he is an editorial board member for the International Journal of General Medicine and Pharmacy (IJGMP).
Nguyen received her doctorate in organic chemistry from the University of Arkansas and her Bachelor of Science in chemistry from Henderson State University. Under the supervision of Professor Nan Zheng, her doctoral research focused on developing efficient one-step syntheses of structurally diverse amino-substituted carbo-and hetero- cycles using visible light photocatalysis. After completing her doctorate, Nguyen joined Southern Research in September 2016 as a postdoctoral fellow. She is currently working in the area of antiviral drug discovery in the Antiviral Drug Discovery and Development Center (AD3C), one of the Centers of Excellence for Translation Research (CETR), funded through NIAID, NIH. She is responsible for providing synthetic chemistry efforts of various target compounds as potential therapeutics for the treatment of Venezuelan equine encephalitis virus (VEEV). Publications: NCBI, Google Scholar
Pathak received her master’s in organic chemistry from the University of Lucknow, India. She has gained more than 20 years of research experience in organic synthesis and medicinal chemistry, including the design, synthesis, and characterization of a wide variety of compounds such as natural products, carbohydrates, nucleosides and small molecules for the utilization in the development of novel drugs. Prior to joining SR in 2009, she was a faculty assistant at Western Illinois University, Macomb, Illinois. Pathak worked in several research laboratories in India, Japan and in the U.S., conducting research in many areas such as anti-infectives and anti-cancer drug discovery programs. Some of the recent drug discovery projects she has worked on include: the synthesis of saponin-based vaccine adjuvants; design and synthesis of quinazoline-based chemical libraries as allosteric modulators of biogenic amine transporters; and design and synthesis of benzimidazole-based Wnt inhibitors for the treatment of pancreatic and colon cancers. She has more than 49 peer-reviewed research publications, presentations and patent applications. Publications: NCBI, Google Scholar
Anish K. Vadukoot earned his Doctorate in Chemistry (August 2016) under the guidance of Dr. Edward J. Merino from University of Cincinnati. His work involved design and development of novel chemical scaffolds to effectively and selectively target cancer cells through Reactive Oxygen Species (ROS) induced apoptotic signaling. Dr. Vadukoot next completed a Postdoctoral Fellowship at University of Nebraska Medical Center (UNMC) from August 2016-March 2019, under the supervision of Dr. Corey R. Hopkins. In this role, he was extensively trained in medicinal chemistry, pharmacokinetics (in vitro and in vivo), and drug discovery and development of novel lead scaffolds for various CNS-related disorders (Parkinson’s, GIRK1/2 activators as novel anxiolytics, Chronic Obstructive Pulmonary Disease). He joined Southern Research as Scientist I in March 2019 where his current research involves the design, synthesis and development of novel anti-HIV agents. He also provides medicinal chemistry efforts in the area of antiviral drug discovery for the Antiviral Drug Discovery and Development Center (AD3C), a Center of Excellence for Translation Research (CETR), funded through NIAID, NIH.